AM6 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Amicus Therapeutics Inc

Watchlist Manager

Watchlist

Price: 12.295 EUR Market Closed

Market Cap: €3.6B

A	Amicus Therapeutics Inc F:AM6	US
M	Mesoblast Ltd OTC:MEOBF	AU
L	Longvie SA BCBA:LONG	AR

Profitability Summary

Amicus Therapeutics Inc's profitability score is 29/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

89%

Strong 3Y Average Gross Margin

90%

Declining Gross Margin

90% > 89%

Low Operating Margin

Negative 3Y Average Operating Margin

-1%

Operating Margin is Increasing

-31% > 5%

Negative Net Margin

-4%

Negative 3Y Average Net Margin

-17%

Net Margin is Increasing

-47% > -4%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-7%

Free Cash Flow Margin is Increasing

-43% > 5%

Negative ROE

-12%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-88%

Declining ROIC

-25% > -852%

View All

Hide

Collapse

29 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.